Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease.
- Author:
Xiao-Hui WANG
1
;
Wei YANG
;
Jin-Shun QI
Author Information
1. Department of Physiology, Key Laboratory for Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.
- Publication Type:Journal Article
- MeSH:
Alzheimer Disease;
drug therapy;
physiopathology;
Amyloid beta-Peptides;
drug effects;
metabolism;
Animals;
Brain;
metabolism;
Diabetes Mellitus, Type 2;
physiopathology;
Glucagon-Like Peptide 1;
pharmacology;
therapeutic use;
Glucagon-Like Peptide-1 Receptor;
Humans;
Neuroprotective Agents;
pharmacology;
therapeutic use;
Receptors, Glucagon;
metabolism
- From:
Acta Physiologica Sinica
2010;62(5):398-406
- CountryChina
- Language:Chinese
-
Abstract:
There is a close correlation between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) in the course of pathophysiological processes. The neuroprotective action of glucagon-like peptide 1 (GLP-1), a latest drug for clinical treatment of T2DM, is being more deeply investigated at present, and a novel therapeutic strategy for AD with GLP-1 has been proposed boldly. This review mainly discussed the correlation of pathogenesis between T2DM and AD, the synthesis and secretion of GLP-1, the distribution and physiological effects of GLP-1 receptor in the brain, and the progresses on the study of GLP-1 in the treatment of AD.
